Investigators, led by Hong Kong researcher and Grail collaborator Dennis Lo, described a cancer detection strategy using cleavage patterns in circulating DNA molecules.
Though there are few direct hints at how the company plans to translate its findings to a clinical test, its early data has captured the attention of the cancer community.
The recent agreement between Freenome and Biognosys suggests a role for proteomics as developers of genomic-based cancer detection tests look beyond ctDNA.
Technologies gained one of their first solid footholds in the clinical care of cancer patients with adoption into the treatment paradigm of lung cancer, while researchers turned their eyes to proving utility in other niches.
